Oral insulin products are under investigation and, once approved, will emerge as new-generation drugs for diabetes management. For instance, Generex Biotechnology Corporation’s Oral-Lyn, Oramed Pharmaceutical's ORMD-0801 and ORMD-0901, and Biocon’s IN-105 are the upcoming oral drugs for the treatment of diabetes.An increase in the number of academia-industry collaborations will ease the process of drug development. Key players in the market are increasing research collaboration with universities and academic institutes. For instance, Sanofi Diabetes collaborated with Helmholtz Zentrum München, Charité, and the University of Copenhagen to support R&D activities and also to identify new targets for diabetes. Also, Novo Nordisk collaborated with Juvenile Diabetes Research Foundation International (JDRF) for diabetes research. Such academia-industry collaborations will result in efficient technology transfer and quicken the drug development process.

PART 01: Executive summary 8

PART 02: Scope of the report 18

Market overview 18

Top-vendor offerings 20

PART 03: Market research methodology 23

Research methodology 23

Economic indicators 23

PART 04: Introduction 24

Key market highlights 24

PART 05: Disease overview: Diabetes 26

Diagnosis of diabetes 26

Complications associated with high blood glucose

levels 27

PART 06: Pipeline portfolio 29

Pipeline for new drug application (NDA) filings 29

Pipeline for Phase III molecules 31

Pipeline for Phase II molecules 32

Pipeline for Phase I molecules 35

Pipeline for pre-clinical stage molecules 36

Pipeline for discovery stage molecules 38

PART 07: Market landscape 39

Market overview 39

Five forces analysis 48

PART 08: Overview of marketed products 49

Synopsis of key diabetic drugs 49

Marketed product profiles 54

PART 09: Market segmentation by type of disease 63

Global type 1 diabetes market 63

Global type 2 diabetes market 66

Global gestational diabetes market 68

PART 10: Market segmentation by drug class 70

Insulin therapies 70

Non-insulin therapies 72

PART 11: Geographical segmentation 75

Diabetic therapeutic market in Americas 77

Diabetic therapeutic market in US 80

Diabetic therapeutic market in EMEA 82

Diabetic therapeutic market in Europe 84

Diabetic therapeutic market in Germany 87

Diabetic therapeutic market in UK 89

Diabetic therapeutic market in France 91

Diabetic therapeutic market in Italy 93

Diabetic therapeutic market in Spain 95

Diabetic therapeutic market in APAC 96

Diabetic therapeutic market in China 99

Diabetic therapeutic market in India 101

PART 12: Market drivers 103

Change in patient preference 103

Focus on self-management of diabetes 104

The strong potential of biologics 104

Unmet medical needs and scope for DMDs 105

PART 13: Impact of drivers 106

PART 14: Market challenges 107

Complex storage conditions and distribution policies for

insulin 107

Unpredictable outcomes on human due to lack of

predictable animal models 107

Gap in nation-level diabetes management plans 108

Rising concerns in the scientific community 108

PART 15: Impact of drivers and challenges 110

PART 16: Market trends 111

Focus on oral insulin therapies 111

Growing technological integration fueling the market

growth 112

Focus on regenerative medicines 114

Strong and diversified pipeline portfolio 116

PART 17: Vendor landscape 117

Competitive scenario 117

Market analysis 2016 119

Upcoming vendors for oral insulin therapies 124

Oramed Pharmaceuticals 124

Generex Biotechnology 127

Other prominent vendors 128

PART 18: Key vendor analysis 143

Novo Nordisk 143

Sanofi 146

Merck 150

Eli Lilly 153

AstraZeneca 157

PART 19: Appendix 162

List of abbreviations 162

PART 20: Explore Technavio 164